Untitled document
PB 73 of 2012
National Health (Prescriber bag supplies) Determination 20121
National Health Act 1953
I, TANYA PLIBERSEK, Minister for Health, make this Determination under sections 93 and 93AB of the National Health Act 1953.
Dated 24th September 2012
TANYA PLIBERSEK
Minister for Health
1 Name of Determination
(1) This Determination is the National Health (Prescriber bag supplies) Determination 2012.
(2) This Determination may also be cited as PB 73 of 2012.
2 Commencement
This Determination commences on 1 October 2012.
3 Revocation
PB 103 of 2010 (Determinations — Pharmaceutical benefits supplied by medical practitioners and authorised nurse practitioners) is revoked.
4 Definitions
In this Instrument:
Act means the National Health Act 1953.
authorised midwife has the same meaning as in subsection 84(1) of the Act.
authorised nurse practitioner has the same meaning as in subsection 84(1) of the Act.
prescriber bag supplier in relation to a pharmaceutical benefit means a medical practitioner, authorised midwife or authorised nurse practitioner authorised to supply the pharmaceutical benefit under this Determination.
maximum quantity means maximum quantity or number of units.
pharmaceutical benefit has the same meaning as in subsection 84(1) of the Act.
pharmaceutical benefit has a drug has the same meaning as in subsection 84(1) of the Act.
prescriber bag provisions has the same meaning as in subsection 84(1) of the Act.
5 Pharmaceutical benefits
(1) For subsection 93(1) of the Act, a medical practitioner is authorised to supply a pharmaceutical benefit having a drug in a form mentioned in the Schedule if the initials MP are mentioned for the drug and the form in the column headed ‘Prescriber Bag Supplier’ in the Schedule.
(2) For subsection 93AB(1) of the Act, an authorised nurse practitioner is authorised to supply a pharmaceutical benefit having a drug in a form mentioned in the Schedule if the initials NP are mentioned for the drug and the form in the column headed ‘Prescriber Bag Supplier’ in the Schedule.
Note: A pharmaceutical benefit is a brand of a drug in a form with a manner of administration. The drugs are declared, and the forms, manners of administration and brands are determined, by legislative instrument under subsections 85(2), (3), (5) and (6) of the Act, respectively.
6 Maximum quantity
(1) The maximum quantity of pharmaceutical benefits having a drug in a form mentioned in the Schedule which may be obtained by a prescriber bag supplier in any calendar month is the quantity mentioned for the drug and the form in the Schedule under the column headed ‘Maximum Quantity’.
(2) The maximum quantity may be obtained for one pharmaceutical benefit only having a drug in a form mentioned in a Group during a calendar month.
(3) A quantity, up to the maximum quantity, for a pharmaceutical benefit may be obtained at a particular time only if, at that time, the total quantity of every pharmaceutical benefit having a particular drug in a particular form in the Group, previously obtained in accordance with the prescriber bag provisions of the Act and still in the possession of the supplier, is less than the maximum quantity for a pharmaceutical benefit having that drug in that form.
(4) For this section, a Group is each drug in a form mentioned in the Schedule which has the same number mentioned in the column headed ‘Group Number’.
Schedule Pharmaceutical benefits that may be supplied by prescriber bag suppliers
| Group Number | Listed Drug | Form | Prescriber Bag Supplier | Maximum Quantity |
| 1 | Adrenaline | Injection 1 mg (as acid tartrate) in 1 mL (1 in 1,000) | MP, NP | 5 |
| 2 | Atropine | Injection containing atropine sulfate 600 micrograms in 1 mL | MP, NP | 10 |
| 3 | Benztropine | Injection containing benztropine mesylate 2 mg in 2 mL | MP, NP | 5 |
| 4 | Benzylpenicillin | Powder for injection 600 mg (as sodium) | MP, NP | 10 |
| 4 | Procaine Penicillin | Injection 1.5 g in disposable syringe | MP, NP | 5 |
| 5 | Benzylpenicillin | Powder for injection 3 g (as sodium) | MP, NP | 1 |
| 6 | Chlorpromazine | Injection containing chlorpromazine hydrochloride 50 mg in 2 mL | MP, NP | 10 |
| 6 | Haloperidol | Injection 5 mg in 1 mL | MP, NP | 10 |
| 7 | Clonazepam | Oral liquid 2.5 mg per mL, 10 mL | MP, NP | 1 |
| 8 | Dexamethasone | Injection containing dexamethasone sodium phosphate equivalent to 4 mg dexamethasone phosphate in 1 mL | MP, NP | 5 |
| 8 | Hydrocortisone | Injection 100 mg (as sodium succinate) with 2 mL solvent | MP, NP | 2 |
| 8 | Hydrocortisone | Injection 250 mg (as sodium succinate) with 2 mL solvent | MP, NP | 1 |
| 9 | Diazepam | Injection 10 mg in 2 mL | MP, NP | 5 |
| 10 | Diphtheria and tetanus vaccine, adsorbed, diluted for adult use | Injection 0.5 mL in pre-filled syringe | MP, NP | 20 |
| 11 | Frusemide | Injection 20 mg in 2 mL | MP, NP | 5 |
| 12 | Glucagon | Injection set containing glucagon hydrochloride 1 mg (1 I.U.) and 1 mL solvent in disposable syringe | MP, NP | 1 |
| 13 | Glyceryl Trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | MP, NP | 1 |
| 14 | Hyoscine | Injection containing hyoscine butylbromide 20 mg in 1 mL | MP, NP | 5 |
| 15 | Lignocaine | Injection containing lignocaine hydrochloride 100 mg in 5 mL | MP, NP | 5 |
| 16 | Methoxyflurane | Liquid for inhalation 999.9 mg per g, 3 mL (with inhaler) | MP | 1 |
| 17 | Metoclopramide | Injection containing metoclopramide hydrochloride 10 mg in 2 mL | MP, NP | 10 |
| 17 | Prochlorperazine | Injection containing prochlorperazine mesylate 12.5 mg in 1 mL | MP, NP | 10 |
| 18 | Morphine | Injection containing morphine sulfate 15 mg in 1 mL | MP, NP | 5 |
| 18 | Morphine | Injection containing morphine sulfate 30 mg in 1 mL | MP, NP | 5 |
| 19 | Naloxone | Injection containing naloxone hydrochloride 2 mg in 5 mL disposable injection set | MP, NP | 2 |
| 20 | Promethazine | Injection containing promethazine hydrochloride 50 mg in 2 mL | MP, NP | 10 |
| 21 | Salbutamol | Pressurised inhalation 100 micrograms (as sulfate) per dose, 200 doses (CFC-free formulation) | MP, NP | 1 |
| 21 | Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 30 | MP, NP | 1 |
| 22 | Salbutamol | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 30 | MP, NP | 1 |
| 23 | Terbutaline | Injection containing terbutaline sulfate 500 micrograms in 1mL | MP, NP | 5 |
| 24 | Tramadol | Injection containing tramadol hydrochloride 100 mg in 2 mL | MP, NP | 5 |
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See
0
0
0